Company Overview and News

52
Tintri: Bankruptcy Official, Creditor Stack Is Deep

2018-07-11 seekingalpha
Tintri formally filed for a Chapter 11 bankruptcy on July 10, one year after its IPO and ten years after its founding.
PSTG TNTR

63
TNTR / Tintri, Inc. 8-K (Current Report)

2018-07-10 sec.gov
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
TNTR

88
Domo: After Steep Fall, Acquisition Potential Sets A Floor For Valuation

2018-07-05 seekingalpha
In its first week of trading, business intelligence software company Domo has seesawed, rising sharply on its first day of trading and then giving up all of those gains.
ZUO APRN TNTR DATA DOCU CRM ADBE AVLR SAP DBX T DOMO MSFT DHR ORCL EBAY SNAP

6
Tintri: CEO Exit And Manufacturing Breach Signal The End

2018-07-02 seekingalpha
Tintri's chances of survival have been reduced to nearly zero, with its CEO resigning after just three months on the job and a mass layoff of 80% of the headcount.
TNTR RHT

40
TNTR / Tintri, Inc. 8-K (Current Report)

2018-06-27 sec.gov
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
TNTR

22
TNTR / Tintri, Inc. FORM 8-K (Current Report)

2018-06-22 sec.gov
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
TNTR

23
TNTR / Tintri, Inc. FORM 8-K (Current Report)

2018-06-19 sec.gov
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
TNTR

12
Tintri: No Hope For An Acquisition In Its Final Days

2018-06-18 seekingalpha
Tintri released an 8-K filing that indicated it would not have sufficient liquidity to continue operating past June 30.
PSTG TNTR

32
TNTR / Tintri, Inc. FORM 8-K (Current Report)

2018-06-15 sec.gov
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
TNTR

20
TNTR / Tintri, Inc. NT 10-Q

2018-06-15 sec.gov
NT 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
TNTR

51
TNTR / Tintri, Inc. 10-K/A (Annual Report)

2018-05-31 sec.gov
10-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
TNTR

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

CUSIP: 88770Q105